Article
What every urologist needs to know about SpaceOAR® hydrogel
123
Study data has shown that SpaceOAR® hydrogel significantly improves quality of life for patients with prostate cancer who have undergone radiotherapy. But what does it take to implement this procedure into routine practice, and what can urologists expect regarding reimbursement?
In this supplement, practicing urologists will share perspectives on this procedure, addressing topics that include:
123
Advertorial Supported by: Augmenix
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
Vikram Narayran, MD, on tech-driven changes that are enhancing patient care
Justin Dubin, MD, on leveraging digital tools to improve patient buy-in
Approaching Corticosteroid Selection With Abiraterone in Patients With High-Risk Localized or Locally Advanced Prostate Cancer
Incorporating Micronized Abiraterone and Low-Fat Meal Dosing: Monitoring Efficacy and Tolerability
Betty Wang, MD, and Laura Bukavina, MD, MPH, MSc, discuss ctDNA's role in NMIBC treatment decisions
Andrea Pezzella, MD, URPS, FACOG, discusses Neuspera's integrated sacral neuromodulation system
The Growing Call for Combination Therapy in NMIBC Treatment
Optimizing NMIBC Treatment Through Sequencing and Patient Preference
Mina Fam, MD, on managing expectations around testosterone replacement therapy
Justin Dubin, MD, on the role for AI in patient education
Related Content
